CDEK
← All organizations

NovImmune SA

For profitContributed to NMEWebsite ↗

Also known as: LCB - Novimmune SA | Light Chain Bioscience - Novimmune SA | NovImmune SA | NOVIMMUNE S.A.

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 3

First clinical trial

Jan 1, 2006

First marketed drug

Nov 20, 2018

First NDA

Nov 20, 2018

Last known activity

Apr 12, 2024

Acquired by Swedish Orphan Biovitrum → Advent International on Jun 12, 2019

Timeline

1990s

  1. Jul 1, 1998

    NovImmune SA— Founded

2010s

  1. Nov 20, 2018

    emapalumab-lzsg— Marketing Organization

  2. Nov 20, 2018

    emapalumab-lzsg— NDA Organization

  3. Jun 12, 2019

    Swedish Orphan Biovitrum— Acquired By

2020s

  1. Sep 8, 2021

    Advent International— Now

Drugs by trial phase (8 distinct, 15 trials)

Phase 3 (1 own, 0 via acquisition)

Phase 2 (3 own, 0 via acquisition)

Phase 1 (4 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (1)

Recent trials (16)

Details

Founded
Geneva, CH Jul 1, 1998
First NDA
Nov 20, 2018
Last known activity
Apr 12, 2024

Designations held

  • Orphan drug
  • Priority review
  • Breakthrough therapy